Drug News

Added 2 hours ago Drug news

NICE refuses to recommend Kymriah to treat diffuse large B-cell lymphoma.- Novartis

The National Institute for Health and Care Excellence (NICE), in a draft ruling, has rejected Kymriah (tisagenlecleucel) for use in...

Added 2 hours ago Drug news

Phase III post-hoc analyses of Vyndaqel shows benefits in ATTR-ACT.- Pfizer.

Pfizer announced that additional sensitivity and post-hoc analyses from the Tafamidis Phase III Transthyretin Amyloid Cardiomyopathy (ATTR-ACT) study provide further...

Added 2 hours ago Drug news

European Commission approves Ilumetri to treat psoriasis.- Almirall

Almirall, S.A. has announced that the European Commission (EC) has approved Ilumetri (tildrakizumab), a humanized, high-affinity IL-23p19 monoclonal antibody, for...

Added 2 hours ago Drug news

Complete Response Letter for Ruconest sBLA for expanded indication in hereditary angioedema.- Pharming.

Pharming has received a Complete Response Letter (CRL) from the FDA regarding the supplemental Biologics License Application (sBLA) for Ruconest...

Added 2 hours ago Drug news

JNJ 42756493 filed with the FDA for metastatic urothelial cancer.- Janssen R&D.

Janssen Pharmaceutical announced that a New Drug Application (NDA) has been submitted to the FDA seeking approval of JNJ 42756493...

Added 2 hours ago Drug news

Pooled data from AMAGINE-2 and AMAGINE-3 studies showed Kyntheum cleared psoriasis more effectively than ustekinumab. Leo Pharma

Data presented at the 27th European Academy of Dermatology and Venereology (EADV) in Paris, showed that treatment with LEO Pharma’s...

Added 1 day ago Drug news

Phase III efficacy study of CAM 2038 meets endpoints in chronic low back pain.- Camurus.

Camurus announced positive results from a Phase III efficacy study of CAM 2038, weekly and monthly buprenorphine depots, in opioid...

Added 1 day ago Drug news

BORA trial shows long-term safety and efficacy of Fasenra in patients with eosinophilic asthma.-AstraZeneca

AstraZeneca announced results from the BORA Phase III extension trial evaluating the long-term safety and efficacy of Fasenra (benralizumab) as...

Added 1 day ago Drug news

Phase III trial of ZP 4207 meets primary endpoint in severe hypoglycemia in diabetes.- Zealand Pharma.

Zealand Pharma announced it has achieved primary and key secondary endpoints in the pivotal Phase III trial with ZP 4207...

Added 1 day ago Drug news

EMA validates filing of Empliciti + pomalidomide + low-dose dexamethasone to treat multiple myeloma. BMS

Bristol-Myers Squibb Company announced that the European Medicines Agency (EMA) has validated the Company’s type II variation application for Empliciti...

Search all news articles